Health Agency Pushed to License Cancer Drug Patents to Cut Costs

North America
Written By Justin Mendoza

In a Tuesday letter, nongovernmental organization Knowledge Ecology International, Universities Allied for Essential Medicines, and the Union for Affordable Cancer Treatment urged the Department of Health and Human Services to license patents on the drug Xtandi to outside manufacturers to produce lower-cost versions of the drug.

  • Latest attempt at getting government to help cut Xtandi costs

  • Industry fighting administration over drug pricing plans

The Biden administration is facing a new call to use its government authority to license an Astellas and Pfizer prostate cancer drug for generic manufacturing.

Justin Mendoza
Previous

Transforming Clinical Trial Results: Report
Next

The Ghost Research Haunting Nordic Medical Trials